Biotest AG appointed Ms. Ainhoa Mendizabal (50) to the company's Management Board as Chief Financial Officer (CFO) with effect from 15 February 2023. When Dr. Michael Ramroth was appointed Chief Executive Officer (CEO) on 1 May 2019, he initially continued to perform the duties of Chief Financial Officer in addition to his other duties. In view of the constantly growing reporting requirements, the company has now filled the position of Chief Financial Officer with Ms Mendizabal.

As 'Chief Financial Officer', Ms. Mendizabal will be responsible within the Biotest Group for the areas of finance, including the treasury and tax departments, controlling, investor relations and insurance. Ms Mendizabal has worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A. Since then, Ms Mendizabal has held various executive and managerial roles in the Grifols Group in Germany and in Europe.

Ms. Mendizabal holds a dual Master of Business Administration (Business Administration) in Spain and in Germany.